EcoDrugPlus

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSCCRG00000053839
Gene Symbol: IMPDH1B
1 Cross references
255 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSCCRG00000076447
Gene Symbol: IMPDH1B
1 Cross references
255 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSCCRG00000040358
Gene Symbol: IMPDH2
1 Cross references
199 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSCCRG00000008442
Gene Symbol: IMPDH2
1 Cross references
198 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSCCRG00000021967
Gene Symbol: JAK1
1 Cross references
211 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSCCRG00000033813
Gene Symbol: JAK1
1 Cross references
211 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSCCRG00000060024
Gene Symbol: JAK2A
1 Cross references
197 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSCCRG00000037064
Gene Symbol: JAK2B
1 Cross references
191 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSCCRG00000052623
Gene Symbol: JAK2B
1 Cross references
191 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSCCRG00000020397
Gene Symbol: KITB
1 Cross references
205 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSCCRG00000045498
Gene Symbol: KITB
1 Cross references
204 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCCRG00000040006
Gene Symbol: LYN
1 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).